Co-Diagnostics Faces Immediate Nasdaq Delisting and OTC Transfer Due to Bid Price Non-Compliance

summarizeSummary

Co-Diagnostics, Inc. received a delisting notice from Nasdaq, leading to an immediate suspension of trading on The Nasdaq Capital Market and a transfer to the OTC Pink Limited Information tier.

check_boxKey Events

• Nasdaq Delisting Notice Received

  On January 7, 2026, Co-Diagnostics received written notice from Nasdaq regarding its non-compliance with the minimum bid price rule (5550(a)(2)).

• Immediate Trading Suspension

  Trading of CODX common stock on The Nasdaq Capital Market will be suspended effective at the open of trading on January 14, 2026.

• Transfer to OTC Market

  The company's securities are expected to trade on the Pink Limited Information tier of the OTC Market under its current trading symbol 'CODX'.

• Failed Compliance After Reverse Split

  Despite a 1-for-30 reverse stock split effective January 2, 2026, and the bid price closing above $1.00 since then, the company failed to regain compliance within the extended period.

auto_awesomeAnalysis

Co-Diagnostics, Inc. has received a delisting notice from Nasdaq, resulting in an immediate suspension of trading on The Nasdaq Capital Market. This is a critical event for investors, as delisting to the OTC Pink Limited Information tier significantly reduces liquidity, institutional interest, and the company's ability to raise capital. While the company plans to request a hearing and has seen its bid price above $1.00 following a recent reverse stock split, the immediate suspension of trading on Nasdaq underscores the severity of its non-compliance. The stock is trading near its 52-week low, further highlighting the company's distressed situation.